Protocol: CDISCPILOT01                                                                  Page  1 of 1 
Population: Efficacy 
Table 14-3.08 
ADAS Cog (11) - Change from Baseline to Week 24 in Male Subjects - LOCF 
 
 
[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline 
value as a covariate. 
[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable. 
[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple 
comparisons. 
Source: C:\cdisc_pilot\PROGRAMS\DRAFT\TFLs\rtf_eff1.sas                  21:05 Monday, June 26, 2006 
 
Placebo 
 (N=33)  
Xanomeline 
 Low Dose 
 (N=34)  
Xanomeline 
 High Dose 
 (N=39)  
Baseline 
  n                                   33 
  34 
  39 
  Mean (SD)                           22.8 (13.45) 
  23.3 (14.03) 
  20.8 (11.11) 
  Median (Range)                      19.0 (5;61) 
  21.5 (7;57) 
  17.0 (3;51) 
Week 24 
  n                                   33 
  34 
  39 
  Mean (SD)                           24.7 (13.89) 
  25.7 (14.72) 
  22.7 (12.32) 
  Median (Range)                      20.0 (5;62) 
  24.0 (6;57) 
  21.0 (3;51) 
Change from Baseline 
  n                                   33 
  34 
  39 
  Mean (SD)                            1.9 (6.14) 
   2.5 (5.61) 
   1.8 (3.77) 
  Median (Range)                       1.0 (-11;16) 
   1.0 (-6;14) 
   1.0 (-7;13) 
 
  p-value(Dose Response) [1][2]     
 
 
  0.873 
 
  p-value(Xan - Placebo) [1][3]     
 
   0.712 
   0.915 
   Diff of LS Means (SE)            
 
0.5 (1.30) 
0.1 (1.25) 
   95% CI                           
 
(-2.1;3.1) 
(-2.4;2.6) 
 
  p-value(Xan High - Xan Low) [1][3]
 
 
   0.783 
   Diff of LS Means (SE)            
 
 
-0.3 (1.26) 
   95% CI                           
 
 
(-2.9;2.2) 
 
